Inflammation Off-Switch: Epoxy-Oxylipins Discovery | AcademicJobs
Dive into UCL's breakthrough on epoxy-oxylipins, fat-derived molecules acting as the body's inflammation off-switch, offering new hope for arthritis, heart disease, and more.
No reviews yet. Be the first to rate Olivia!
Olivia Bracken is a post-doctoral researcher in the Department of Ageing, Rheumatology and Regenerative Medicine at University College London. Her research focuses on the biology of T cells in ageing and the mechanisms by which IL-15 drives cytotoxic activity in senescent T cells. She previously conducted her PhD studies in Professor Derek Gilroy’s lab at UCL, investigating the role of inflammatory monocytes in the resolution of inflammation. Bracken supervises master’s and BSc students and lectures on the Fundamental and Applied Immunology module for master’s students.
In 2022, she received the award for best oral presentation for a PhD student at the Versus Arthritis Annual Fellows meeting. As first author, she contributed to research published in 2026 identifying a natural pathway that limits harmful immune cell expansion and helps resolve inflammation more quickly, with potential relevance to conditions such as rheumatoid arthritis. Her professional email address is olivia.bracken.18@ucl.ac.uk.
Dive into UCL's breakthrough on epoxy-oxylipins, fat-derived molecules acting as the body's inflammation off-switch, offering new hope for arthritis, heart disease, and more.
UCL scientists reveal epoxy-oxylipins as the body's inflammation off switch, reducing chronic disease risk via sEH inhibition. Key implications for RA, IBD in UK.